Unite Mixte de Recherche Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Recherche en Canerologie Nantes-Angers, Nantes, France.
Immunotherapy. 2011 Apr;3(4):495-505. doi: 10.2217/imt.11.16.
Adoptive transfer of T cells remains a promising approach in melanoma. Initial clinical trials performed with polyclonal tumor-infiltrating lymphocyte gave limited clinical results. Nonetheless, encouraging results have been reported in adjuvant setting (stage III melanoma), and when tumor-infiltrating lymphocytes were associated with lymphodepleting regimens. Specificity of adoptive cell therapy has been achieved with the infusion of antigen specific cytotoxic T-lymphocyte clones, associated with some clinical responses. Antigen specificity can also be obtained by the allogeneic transfer of high-avidity T-cell receptors into autologous T cells. We propose an alternative strategy based on the selection of antigen-specific T cells with magnetic beads coated with HLA-peptide multimers. Future improvements of adoptive melanoma immunotherapy may be achieved by its association with other therapeutic strategies such as targeted therapy against signaling pathways.
过继性 T 细胞转移在黑色素瘤中仍然是一种很有前途的方法。最初使用多克隆肿瘤浸润淋巴细胞进行的临床研究仅取得了有限的临床效果。然而，在辅助治疗（III 期黑色素瘤）和肿瘤浸润淋巴细胞与淋巴细胞耗竭方案联合应用时，已经报告了令人鼓舞的结果。通过输注与抗原特异性细胞毒性 T 淋巴细胞克隆相关的抗原特异性细胞疗法已经实现了特异性，与一些临床反应相关。通过将高亲和力 T 细胞受体同种异体转移到自体 T 细胞中也可以获得抗原特异性。我们提出了一种基于用 HLA-肽多聚体包被的磁珠选择抗原特异性 T 细胞的替代策略。通过将其与其他治疗策略（如针对信号通路的靶向治疗）联合应用，可能会进一步改善过继性黑色素瘤免疫疗法。
